Mirtazapin Aurobindo (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Aurobindo, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapin Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine, marketed as Mirtazapin Aurobindo, is used in the management of depressive disorders.

- Major depressive disorder: alleviates depressive symptoms and improves mood in affected individuals.

Mirtazapin Aurobindo may be associated with a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Sedation: feeling of drowsiness or sleepiness. - Increased appetite and weight gain: heightened hunger leading to weight increase. - Dry mouth: reduced salivation causing oral dryness. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in white blood cells requiring immediate medical attention. - Seizures: occurrence of convulsive episodes, especially in predisposed individuals. - Suicidal thoughts or behavior: emergence of new or worsening suicidal ideation.

When prescribing Mirtazapin Aurobindo, several safety considerations should be observed. - Pregnancy: Category B – use only if potential benefit justifies the potential risk to the fetus. - Elderly patients: monitor for excessive sedation and increased fall risk. - Renal impairment: consider dose adjustment and monitor renal function. - Concomitant CNS depressants: may potentiate sedation and respiratory depression. - Suicidal ideation: closely observe patients during treatment initiation and dose changes. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Mirtazapin Aurobindo can interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): concurrent use can cause hypertensive crisis or serotonin syndrome. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): increased risk of serotonin syndrome. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., carbamazepine, phenytoin): may reduce therapeutic effectiveness. - Alcohol: additive central nervous system depression leading to enhanced sedation.